



(12) Translation of
European patent specification

(11) NO/EP 4015527 B1

NORWAY

(19) NO
(51) Int Cl.
C12N 9/10 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2025.04.14
(80)	Date of The European Patent Office Publication of the Granted Patent	2025.01.22
(86)	European Application Nr.	21212873.0
(86)	European Filing Date	2009.04.16
(87)	The European Application's Publication Date	2022.06.22
(30)	Priority	2008.04.25, EP, 08251528 2008.04.16, US, 45424 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
(62)	Divided application	EP3098234, 2009.04.16
(73)	Proprietor	Ferring B.V., Polaris Avenue 144, 2132 JX Hoofddorp, Nederland
(72)	Inventor	COTTINGHAM, Ian, 1162 Saint-Prex, Sveits PLAKSIN, Daniel, 1162 Saint-Prex, Sveits WHITE, Richard Boyd, deceased, USA
(74)	Agent or Attorney	RWS, RWS Compass House, Vanwall Business Park, Vanwall Road, SL64UB MAIDENHEAD, BERKSHIRE, Storbritannia

(54)	Title	RECOMBINANT FSH INCLUDING ALPHA 2,3- AND ALPHA 2,6-SIALYLATION
------	-------	---

(56)	References Cited:	WO-A2-03/035686 WO-A1-2012/016576 DICKY RICHARD P ET AL: "Highly purified human-derived follicle-stimulating hormone (Bravelle(R)) has equivalent efficacy to follitropin-beta (Follistim (R)) in infertile women undergoing in vitro fertilization", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, BIOMED CENTRAL LTD, GB, vol. 1, no. 1, 63, 3 October 2003 (2003-10-03), pages 1 - 8, XP021009333, ISSN: 1477-7827, DOI: 10.1186/1477-7827-1-63 FLACK M R ET AL: "Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM SEP 1994, vol. 79, no. 3, September 1994 (1994-09-01), pages 756 - 760, XP002494715, ISSN: 0021-972X
------	----------------------	--

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Rekombinant FSH (rFSH) som inkluderer α 2,3- og α 2,6-sialylering hvori fra 10 % til 30 % av den totale sialyleringen er α 2,6-sialylering.

5

2. Rekombinant FSH (rFSH) ifølge krav 1 fremstilt eller uttrykt i en human cellelinje.

3. Farmasøytisk sammensetning omfattende rekombinant FSH ifølge et hvilket som helst foregående krav.

10

4. Farmasøytisk sammensetning ifølge krav 3, videre omfattende hCG og/eller LH.

5. Farmasøytisk sammensetning ifølge krav 3 eller krav 4 for anvendelse i behandlingen av ufruktbarhet.